Integra LifeSciences Corp - Kewajiban jangka dawa perusahaan IART

Integra LifeSciences (IART) maintains a balanced structure through a combination of regenerative technologies and neurosurgery, which minimizes regulatory threats. This chart from GURU.Markets illustrates the price action of the company, whose long-term debt stands at 1.98. The business relies on the development of advanced biomatrices and high-precision instrumentation, while implementing sustainable manufacturing standards and energy-efficient solutions to minimize production waste.

Long-term debt reflects the total obligations with maturities exceeding one year, allowing for an assessment of the issuer's financial leverage and capital structure stability. By analyzing the current level of long-term debt at Integra LifeSciences (IART), an investor can identify the resource base used to fund high-tech developments in neurosurgery and the expenses required to retain leading bioengineers through a system of grants and stock options.